Sun Pharma Pulls Multiple Eye Drops Across India Over Contamination Fears

India's pharmaceutical giant, Sun Pharma, has initiated a nationwide recall of several popular eye drop brands, including Lotepred and Nepalact, following concerns over potential contamination risks. This urgent move, which began with a confidential letter to distributors on July 17, 2026, aims to safeguard patient safety and uphold essential regulatory quality standards amidst worries about product integrity. The recall impacts a wide range of formulations vital for patients recovering from eye surgery or managing chronic conditions like glaucoma and ocular inflammation, meaning an interruption in treatment could have serious consequences. This development places Sun Pharma under heightened scrutiny regarding its manufacturing facilities and quality control, especially given a broader industry trend of Indian drugmakers facing increased regulatory checks both domestically and internationally. The Central Drugs Standard Control Organisation (CDSCO) is closely monitoring the situation as experts stress that maintaining sterility in ophthalmic products is non-negotiable for public health. Patients currently using the affected eye drops are strongly advised not to abruptly stop their treatment but to consult their eye doctors immediately for safe alternatives to avoid any health risks. Sun Pharma teams are working to restore the supply chain for these critical medications, with the full financial and reputational fallout for the company still unfolding. This incident highlights the ongoing imperative for stringent quality assurance across India's vast pharmaceutical landscape to maintain trust among millions of users globally.